Takeda first shone a spotlight on Finch Therapeutics’ human-first discovery platform in 2017, when the Japanese pharma paid $10 million to partner a preclinical ulcerative colitis program inspired by fecal transplantation. While the microbiome therapy, FIN-524, is still making its way to the clinic, Takeda has seen enough to commit to a second program tackling another type of inflammatory bowel disease.
Copyright © 2021,